TY - JOUR
T1 - Targeting IL-6 in cholangiocarcinoma therapy
AU - Mott, Justin L.
AU - Gores, Gregory J.
PY - 2007/10
Y1 - 2007/10
N2 - In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.
AB - In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.
UR - http://www.scopus.com/inward/record.url?scp=34848816778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848816778&partnerID=8YFLogxK
U2 - 10.1111/j.1572-0241.2007.01394.x
DO - 10.1111/j.1572-0241.2007.01394.x
M3 - Review article
C2 - 17897336
AN - SCOPUS:34848816778
SN - 0002-9270
VL - 102
SP - 2171
EP - 2172
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 10
ER -